Erwinaze
FDA Approves Gleevec for Children with Acute Lymphoblastic Leukemia »
"The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
ALL is the most common type of pediatric "...
Read the FDA Approves Gleevec for Children with Acute Lymphoblastic Leukemia article »
Erwinaze
ERWINAZE
(asparaginase Erwinia chrysanthemi) for injection, intramuscular use
DRUG DESCRIPTION
ERWINAZE (asparaginase Erwinia chrysanthemi) contains an asparaginase specific enzyme derived from Erwinia chrysanthemi. L-asparaginase is a tetrameric enzyme consisting of four identical subunits, each having a molecular weight of about 35 kDa. The activity of ERWINAZE is expressed in terms of International Units.
ERWINAZE is supplied as a sterile, lyophilized, white powder in vials. Each vial contains 10,000 International Units of asparaginase Erwinia chrysanthemi and the following inactive ingredients: glucose monohydrate (5.0 mg), sodium chloride (0.5 mg).
Last reviewed on RxList: 12/5/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Erwinaze Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
